<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30183988</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>18</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>18</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1678-4170</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>111</Volume>                    <Issue>2</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Aug</Month>                    </PubDate>                </JournalIssue>                <Title>Arquivos brasileiros de cardiologia</Title>                <ISOAbbreviation>Arq. Bras. Cardiol.</ISOAbbreviation>            </Journal>            <ArticleTitle>Antiplatelet Therapy in Breast Cancer Patients Using Hormonal Therapy: Myths, Evidence and Potentialities - Systematic Review.</ArticleTitle>            <Pagination>                <MedlinePgn>205-212</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0066-782X2018001400205</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.5935/abc.20180138</ELocationID>            <Abstract>                <AbstractText>Breast cancer is the most frequently diagnosed tumor in women worldwide, with a significant impact on morbidity and mortality. Chemotherapy and hormone therapy have significantly reduced mortality; however, the adverse effects are significant. Aspirin has been incorporated into clinical practice for over 100 years at a low cost, making it particularly attractive as a potential agent in breast cancer prevention and as an adjunct treatment to endocrine therapy in the prophylaxis of cardiovascular complications. The objective of this study was to evaluate the role of aspirin in reducing the incidence of breast cancer and to evaluate the impact of its use on morbidity and mortality and reduction of cardiovascular events as adjuvant therapy during breast cancer treatment with selective estrogen receptor modulators. A systematic review was performed using the PRISMA methodology and PICO criteria, based on the MEDLINE, EMBASE and LILACS databases. The original articles of clinical trials, cohort, case-control studies and meta-analyses published from January 1998 to June 2017, were considered. Most studies showed an association between the use of selective estrogen receptor modulators and the increase in thromboembolic events. The studies suggest a protective effect of aspirin for cardiovascular events during its concomitant use with selective estrogen receptor modulators and in the prevention of breast cancer. This systematic review suggests that aspirin therapy combines the benefit of protection against cardiovascular events with the potential reduction in breast cancer risk, and that the evaluation of the benefits of the interaction of endocrine therapy with aspirin should be further investigated.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Leite</LastName>                    <ForeName>Andréa de Melo</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-graduação em Ciências Cardiovasculares da Universidade Federal Fluminense (UFF), Niterói, RJ - Brazil.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Rede D'Or São Luiz, Rio de Janeiro, RJ - Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Macedo</LastName>                    <ForeName>Ariane Vieira Scarlatelli</ForeName>                    <Initials>AVS</Initials>                    <AffiliationInfo>                        <Affiliation>Grupo Oncoclínicas do Brasil, Belo Horizonte, MG - Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jorge</LastName>                    <ForeName>Antonio José Lagoeiro</ForeName>                    <Initials>AJL</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-graduação em Ciências Cardiovasculares da Universidade Federal Fluminense (UFF), Niterói, RJ - Brazil.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Martins</LastName>                    <ForeName>Wolney de Andrade</ForeName>                    <Initials>WA</Initials>                    <AffiliationInfo>                        <Affiliation>Programa de Pós-graduação em Ciências Cardiovasculares da Universidade Federal Fluminense (UFF), Niterói, RJ - Brazil.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <Language>por</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D016454">Review</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>Brazil</Country>            <MedlineTA>Arq Bras Cardiol</MedlineTA>            <NlmUniqueID>0421031</NlmUniqueID>            <ISSNLinking>0066-782X</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D010975">Platelet Aggregation Inhibitors</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>R16CO5Y76E</RegistryNumber>                <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2012 Jun;23(6):1403-15</RefSource>                <PMID Version="1">22517822</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2002 Sep 14;360(9336):817-24</RefSource>                <PMID Version="1">12243915</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cardiovasc Pharmacol. 2007 Oct;50(4):380-90</RefSource>                <PMID Version="1">18049305</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2000 Apr 1;95(7):2289-96</RefSource>                <PMID Version="1">10733498</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Blood. 2005 Jan 1;105(1):115-21</RefSource>                <PMID Version="1">15198955</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2004 Dec 1;96(23):1751-61</RefSource>                <PMID Version="1">15572757</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309</RefSource>                <PMID Version="1">21743022</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2009 May;10(5):501-7</RefSource>                <PMID Version="1">19410194</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2006 Jun 21;295(23):2727-41</RefSource>                <PMID Version="1">16754727</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2005 May 9;92(9):1614-20</RefSource>                <PMID Version="1">15841078</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Climacteric. 2007 Apr;10(2):97-111</RefSource>                <PMID Version="1">17453858</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2008 May 15;14(10):3070-6</RefSource>                <PMID Version="1">18483373</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Am J Clin Oncol. 2015 Dec;38(6):641-4</RefSource>                <PMID Version="1">25503435</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2011 Aug 27;378(9793):771-84</RefSource>                <PMID Version="1">21802721</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Transl Sci. 2013 Oct;6(5):386-90</RefSource>                <PMID Version="1">24127927</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2011 Jan 1;377(9759):31-41</RefSource>                <PMID Version="1">21144578</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2016 Apr 20;11(4):e0152402</RefSource>                <PMID Version="1">27096951</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2006 Jul 13;355(2):125-37</RefSource>                <PMID Version="1">16837676</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Curr Oncol Rep. 2017 Jul;19(7):48</RefSource>                <PMID Version="1">28597105</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2004 Dec 1;96(23):1762-9</RefSource>                <PMID Version="1">15572758</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 May 2;8(18):30252-30264</RefSource>                <PMID Version="1">28415819</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Intern Med. 2013 Apr 16;158(8):604-14</RefSource>                <PMID Version="1">23588749</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2007 Feb 21;99(4):272-82</RefSource>                <PMID Version="1">17312304</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Neurology. 2004 Oct 12;63(7):1230-3</RefSource>                <PMID Version="1">15477543</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2009 Jun;115(3):643-50</RefSource>                <PMID Version="1">19082882</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Intern Med. 2009 Aug 18;151(4):264-9, W64</RefSource>                <PMID Version="1">19622511</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2003;5(3):140-6</RefSource>                <PMID Version="1">12793895</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Thromb Res. 2012 Jan;129(1):36-42</RefSource>                <PMID Version="1">21875743</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2004 Oct 20;96(20):1528-36</RefSource>                <PMID Version="1">15494603</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2001 Jan;65(2):125-34</RefSource>                <PMID Version="1">11261828</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arterioscler Thromb Vasc Biol. 2017 Apr;37(4):664-674</RefSource>                <PMID Version="1">28153880</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 1999 Jan-Feb;6(1):71-3</RefSource>                <PMID Version="1">9864404</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):239-42</RefSource>                <PMID Version="1">22068285</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2014 Jul 29;111(3):623-7</RefSource>                <PMID Version="1">24945997</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Platelets. 2003 Mar;14(2):75-81</RefSource>                <PMID Version="1">12745449</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2011 Feb;11(2):123-34</RefSource>                <PMID Version="1">21258396</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88</RefSource>                <PMID Version="1">9747868</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Oncol. 2004 Feb;15(2):211-7</RefSource>                <PMID Version="1">14760111</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2010 Mar 20;28(9):1467-72</RefSource>                <PMID Version="1">20159825</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2012 May;13(5):518-27</RefSource>                <PMID Version="1">22440112</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Womens Health (Larchmt). 2017 Dec;26(12):1278-1284</RefSource>                <PMID Version="1">28537451</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Womens Health (Larchmt). 2010 Aug;19(8):1459-65</RefSource>                <PMID Version="1">20626269</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2001 Jan 3;93(1):16-21</RefSource>                <PMID Version="1">11136837</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2005 Nov 2;97(21):1609-10</RefSource>                <PMID Version="1">16264181</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2005 May 14-20;365(9472):1687-717</RefSource>                <PMID Version="1">15894097</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2005 Mar 15;103(6):1114-21</RefSource>                <PMID Version="1">15712362</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2003 Sep 15;63(18):6096-101</RefSource>                <PMID Version="1">14522941</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2013 May 25;381(9880):1827-34</RefSource>                <PMID Version="1">23639488</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocr Rev. 1999 Jun;20(3):253-78</RefSource>                <PMID Version="1">10368771</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2008 Oct 15;100(20):1439-47</RefSource>                <PMID Version="1">18840819</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 1999 Jun 16;281(23):2189-97</RefSource>                <PMID Version="1">10376571</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2014 Jun 02;14:391</RefSource>                <PMID Version="1">24890520</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1586-91</RefSource>                <PMID Version="1">12496048</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocr Rev. 1999 Jun;20(3):418-34</RefSource>                <PMID Version="1">10368777</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thromb Haemost. 2009 Nov;7(11):1759-66</RefSource>                <PMID Version="1">19691483</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001241" MajorTopicYN="N">Aspirin</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010975" MajorTopicYN="N">Platelet Aggregation Inhibitors</DescriptorName>                <QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>10</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>06</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30183988</ArticleId>            <ArticleId IdType="pii">S0066-782X2018001400205</ArticleId>            <ArticleId IdType="doi">10.5935/abc.20180138</ArticleId>            <ArticleId IdType="pmc">PMC6122903</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>